CTLA4 and colitis: Another group similarly found that genera Faecalibacterium and Gemminger were associated with progression-free survival of at least six months following anti-CTLA-4 immunotherapy, and that while genera Faecalibacterium, Lachnospiracae, and Gemminger were increased and genus Prevotella was decreased in patients with colitis, this was not significant124.